Home Applications 021338 Application 021338
Type NDA
Sponsor THE MEDICINES CO Application Products# Product, Drug, Ingredient table Product Drug Ingredient Form Strength Reference drug Reference standard 001 IONSYS FENTANYL HYDROCHLORIDE SYSTEM;IONTOPHORESIS, TRANSDERMAL EQ 40MCG BASE/ACTIVATION Yes No
Source provenance: Browse the complete Orange Book source catalog · source snapshot 44 .
Orange Book products# Current product rows page 1 of 1 · 1 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N021338-001 IONSYS FENTANYL HYDROCHLORIDE EQ 40MCG BASE/ACTIVATION SYSTEM / IONTOPHORESIS, TRANSDERMAL RLD 2006-05-22
Orange Book patents# Current patent rows page 1 of 1 · 7 matching rows.
Application-product, Patent, Expiration table Application-product Patent Expiration Use code Coverage / status Submission date N021338-001 8301238 2031-09-30 Drug product N021338-001 9364656 2031-09-30 U-736 2016-06-21 N021338-001 9731121 2031-10-17 Drug product 2017-09-12 N021338-001 8781571 2032-03-31 U-736 Drug product 2015-05-28 N021338-001 8428708 2032-05-21 U-736 N021338-001 8428709 2032-06-11 U-736 Drug product 2015-05-28 N021338-001 9095706 2033-02-03 Drug product 2015-08-06
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 2 of 2 · 44 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2022-10-28 04:53 UTC 2022-10 N021338-001 IONSYS EQ 40MCG BASE/ACTIVATION SYSTEM / IONTOPHORESIS, TRANSDERMAL RLD 2006-05-22 f41ea6bd6efb…2022-09-29 23:25 UTC 2022-09 N021338-001 IONSYS EQ 40MCG BASE/ACTIVATION SYSTEM / IONTOPHORESIS, TRANSDERMAL RLD 2006-05-22 e64feba35796…2022-07-09 03:26 UTC · 3 captures of this ZIP 2022-07 N021338-001 IONSYS EQ 40MCG BASE/ACTIVATION SYSTEM / IONTOPHORESIS, TRANSDERMAL RLD 2006-05-22 cb3db0bc1861…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N021338-001 IONSYS EQ 40MCG BASE/ACTIVATION SYSTEM / IONTOPHORESIS, TRANSDERMAL RLD 2006-05-22 a50c72e98297…
Observed Orange Book patent history# Patent history page 1 of 10 · 369 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-10-15 13:18:30 2026-09 N021338-001 8301238 2031-09-30 Drug product c2088c7a36db…2026-10-15 13:18:30 2026-09 N021338-001 9364656 2031-09-30 U-736 2016-06-21 c2088c7a36db…2026-10-15 13:18:30 2026-09 N021338-001 9731121 2031-10-17 Drug product 2017-09-12 c2088c7a36db…2026-10-15 13:18:30 2026-09 N021338-001 8781571 2032-03-31 U-736 Drug product 2015-05-28 c2088c7a36db…2026-10-15 13:18:30 2026-09 N021338-001 8428708 2032-05-21 U-736 c2088c7a36db…2026-10-15 13:18:30 2026-09 N021338-001 8428709 2032-06-11 U-736 Drug product 2015-05-28 c2088c7a36db…2026-10-15 13:18:30 2026-09 N021338-001 9095706 2033-02-03 Drug product 2015-08-06 c2088c7a36db…2026-09-14 22:38:34 2026-08 N021338-001 8301238 2031-09-30 Drug product 84e616aacf4f…2026-09-14 22:38:34 2026-08 N021338-001 9364656 2031-09-30 U-736 2016-06-21 84e616aacf4f…2026-09-14 22:38:34 2026-08 N021338-001 9731121 2031-10-17 Drug product 2017-09-12 84e616aacf4f…2026-09-14 22:38:34 2026-08 N021338-001 8781571 2032-03-31 U-736 Drug product 2015-05-28 84e616aacf4f…2026-09-14 22:38:34 2026-08 N021338-001 8428708 2032-05-21 U-736 84e616aacf4f…2026-09-14 22:38:34 2026-08 N021338-001 8428709 2032-06-11 U-736 Drug product 2015-05-28 84e616aacf4f…2026-09-14 22:38:34 2026-08 N021338-001 9095706 2033-02-03 Drug product 2015-08-06 84e616aacf4f…2026-08-18 06:07:40 2026-07 N021338-001 8301238 2031-09-30 Drug product caaa826d4ba7…2026-08-18 06:07:40 2026-07 N021338-001 9364656 2031-09-30 U-736 2016-06-21 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N021338-001 9731121 2031-10-17 Drug product 2017-09-12 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N021338-001 8781571 2032-03-31 U-736 Drug product 2015-05-28 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N021338-001 8428708 2032-05-21 U-736 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N021338-001 8428709 2032-06-11 U-736 Drug product 2015-05-28 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N021338-001 9095706 2033-02-03 Drug product 2015-08-06 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N021338-001 8301238 2031-09-30 Drug product 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N021338-001 9364656 2031-09-30 U-736 2016-06-21 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N021338-001 9731121 2031-10-17 Drug product 2017-09-12 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N021338-001 8781571 2032-03-31 U-736 Drug product 2015-05-28 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N021338-001 8428708 2032-05-21 U-736 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N021338-001 8428709 2032-06-11 U-736 Drug product 2015-05-28 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N021338-001 9095706 2033-02-03 Drug product 2015-08-06 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N021338-001 8301238 2031-09-30 Drug product 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N021338-001 9364656 2031-09-30 U-736 2016-06-21 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N021338-001 9731121 2031-10-17 Drug product 2017-09-12 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N021338-001 8781571 2032-03-31 U-736 Drug product 2015-05-28 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N021338-001 8428708 2032-05-21 U-736 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N021338-001 8428709 2032-06-11 U-736 Drug product 2015-05-28 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N021338-001 9095706 2033-02-03 Drug product 2015-08-06 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 N021338-001 8301238 2031-09-30 Drug product 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N021338-001 9364656 2031-09-30 U-736 2016-06-21 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N021338-001 9731121 2031-10-17 Drug product 2017-09-12 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N021338-001 8781571 2032-03-31 U-736 Drug product 2015-05-28 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N021338-001 8428708 2032-05-21 U-736 6a471c1ec25d…
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
NDC Listings For This Application# NDC listings for this application page 1 of 1 · 1 matching rows.
NDC, Name, Nonproprietary name table NDC Name Nonproprietary name Labeler Marketing category Status 65293-011 IONSYS fentanyl iontophoretic transdermal system The Medicines Company NDA Current
Documents# Document, Submission type, Date table Document Submission type Date 57401 SUPPL 2019-02-01 47829 SUPPL 2017-04-03 46355 SUPPL 2016-12-21 46282 SUPPL 2016-12-20 27516 SUPPL 2015-11-16 23996 ORIG 2015-07-02 15218 SUPPL 2015-05-06 5083 SUPPL 2015-05-04 42108 ORIG 2008-01-16 5082 ORIG 2008-01-16 15217 ORIG 2006-05-24